Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM.

Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.

PMID:
31332390
2.

The double sides of hope: The meaning of hope among amyotrophic lateral sclerosis (ALS) patients.

Hamama-Raz Y, Norden Y, Buchbinder E.

Death Stud. 2019 Jun 13:1-10. doi: 10.1080/07481187.2019.1626946. [Epub ahead of print]

PMID:
31192774
3.

Incest Survivors' Life-Narratives.

Buchbinder E, Sinay D.

Violence Against Women. 2019 May 22:1077801219847295. doi: 10.1177/1077801219847295. [Epub ahead of print]

PMID:
31115275
4.

Experiencing the relationship with a sibling coping with mental health problems: Dilemmas of connection, communication, and role.

Kovacs T, Possick C, Buchbinder E.

Health Soc Care Community. 2019 Sep;27(5):1185-1192. doi: 10.1111/hsc.12761. Epub 2019 Apr 14.

PMID:
30983043
5.

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.

Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA.

J Immunother Cancer. 2019 Mar 29;7(1):89. doi: 10.1186/s40425-019-0512-5.

6.

Immunotherapy Toxicity.

Mantia CM, Buchbinder EI.

Hematol Oncol Clin North Am. 2019 Apr;33(2):275-290. doi: 10.1016/j.hoc.2018.12.008. Epub 2019 Jan 28. Review.

PMID:
30833000
7.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

8.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, CaƱadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
9.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
10.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.

Tan SY, Najita J, Li X, Strazzulla LC, Dunbar H, Lee MY, Seery VJ, Buchbinder EI, Tawa NE, McDermott DF, Lee SJ, Atkins MB, Kim CC.

Melanoma Res. 2019 Feb;29(1):70-76. doi: 10.1097/CMR.0000000000000483.

PMID:
30169431
11.

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145.

12.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

13.

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L.

Cancer Immunol Res. 2017 Dec;5(12):1133-1140. doi: 10.1158/2326-6066.CIR-17-0208. Epub 2017 Oct 27.

14.

Biomarkers in Melanoma: Lessons from Translational Medicine.

Buchbinder EI, Flaherty KT.

Trends Cancer. 2016 Jun;2(6):305-312. doi: 10.1016/j.trecan.2016.05.003. Epub 2016 Jun 2. Review.

PMID:
28741528
15.

An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Erratum in: Nature. 2018 Mar 14;555(7696):402.

16.

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation.

Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD.

Radiother Oncol. 2017 Jul;124(1):98-103. doi: 10.1016/j.radonc.2017.06.006. Epub 2017 Jun 26.

PMID:
28662869
17.

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.

Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS.

Clin Cancer Res. 2017 Aug 15;23(16):4671-4679. doi: 10.1158/1078-0432.CCR-17-0114. Epub 2017 Jun 7.

18.

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA.

J Neurooncol. 2017 May;133(1):221. doi: 10.1007/s11060-017-2485-x. No abstract available.

PMID:
28527005
19.

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M.

Clin Chem. 2017 Jul;63(7):1190-1195. doi: 10.1373/clinchem.2016.267849. Epub 2017 May 17. No abstract available.

20.

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI.

Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10.

21.

Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.

Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, Weinberg J, Donahue H, Bailey N, Hodi FS, Buchbinder EL, Ott PA.

Cancer Immunol Res. 2017 Apr;5(4):286-291. doi: 10.1158/2326-6066.CIR-16-0302.

22.

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ.

J Immunother. 2017 Jan;40(1):31-35.

PMID:
27846054
23.

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

Ibrahim N, Buchbinder EI, Granter SR, Rodig SJ, Giobbie-Hurder A, Becerra C, Tsiaras A, Gjini E, Fisher DE, Hodi FS.

Cancer Med. 2016 Nov;5(11):3041-3050. doi: 10.1002/cam4.862. Epub 2016 Oct 17.

24.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

25.

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA.

J Neurooncol. 2016 Sep;129(3):389-393. doi: 10.1007/s11060-016-2196-8. Epub 2016 Jul 11. Erratum in: J Neurooncol. 2017 May 19;:.

PMID:
27401151
26.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

27.

Attitudes Toward Domestic Violence and Corporal Punishment Among Former Soviet Union Immigrants in Israel.

Enosh G, Leshem E, Buchbinder E.

Violence Against Women. 2016 Oct;22(11):1326-42. doi: 10.1177/1077801215623382. Epub 2016 Feb 1.

PMID:
26834146
28.

Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

Buchbinder EI, Hodi FS.

Nat Rev Clin Oncol. 2016 Feb;13(2):77-8. doi: 10.1038/nrclinonc.2015.237. Epub 2016 Jan 20. No abstract available.

PMID:
26787285
29.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
30.

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Buchbinder EI, Desai A.

Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Review.

31.

The Dialectic of Chaos and Control in the Experience of Therapists Who Work With Sexually Abused Children.

Possick C, Waisbrod N, Buchbinder E.

J Child Sex Abus. 2015;24(7):816-36. doi: 10.1080/10538712.2015.1057667. Epub 2015 Oct 19.

PMID:
26479839
32.
33.

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.

Buchbinder E, Hodi FS.

J Clin Invest. 2015 Sep;125(9):3377-83. doi: 10.1172/JCI80012. Epub 2015 Sep 1. Review.

34.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.

Cancer. 2015 Nov 15;121(22):4007-15. doi: 10.1002/cncr.29622. Epub 2015 Aug 11.

35.

Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis.

Tse JY, Walls BE, Pomerantz H, Yoon CH, Buchbinder EI, Werchniak AE, Dong F, Lian CG, Granter SR.

J Cutan Pathol. 2016 Jan;43(1):57-63. doi: 10.1111/cup.12568. Epub 2015 Sep 21. Review.

PMID:
26260725
36.

Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.

Buchbinder EI, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):755-63. doi: 10.1016/j.clinthera.2015.02.003. Epub 2015 Mar 6. Review.

PMID:
25746738
37.

From violence to hope: the construction of professional knowledge in treating imprisoned male batterers in Israel.

Enosh G, Buchbinder E, Shafir O.

Int J Offender Ther Comp Criminol. 2014 Oct;58(10):1205-29.

PMID:
25469371
38.

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ.

Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15.

39.

Coping With Stillbirth Among Ultraorthodox Jewish Women.

Hamama-Raz Y, Hartman H, Buchbinder E.

Qual Health Res. 2014 Jul;24(7):923-932. Epub 2014 Jun 3.

PMID:
24894649
40.

Interferon, interleukin-2, and other cytokines.

Buchbinder EI, McDermott DF.

Hematol Oncol Clin North Am. 2014 Jun;28(3):571-83. doi: 10.1016/j.hoc.2014.02.001. Epub 2014 Apr 3. Review.

PMID:
24880948
41.

Re-Experiencing Motherhood: Transformation of Relationships Between Formerly Abused Women and Their Children.

Goldblatt H, Buchbinder E, Cohen R.

Violence Against Women. 2014 May;20(5):561-580. Epub 2014 May 16.

PMID:
24838391
42.
43.

Parents' experience of their child's first psychiatric breakdown: "welcome to hell".

Shpigner E, Possick C, Buchbinder E.

Soc Work Health Care. 2013;52(6):538-57. doi: 10.1080/00981389.2013.780835.

PMID:
23865971
44.

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B.

Br J Haematol. 2013 Feb;160(4):530-7. doi: 10.1111/bjh.12163. Epub 2012 Dec 13.

45.

From hope to despair, and back: being the wife of a patient in a persistent vegetative state.

Hamama-Raz Y, Zabari Y, Buchbinder E.

Qual Health Res. 2013 Feb;23(2):231-40. doi: 10.1177/1049732312467537. Epub 2012 Nov 27.

PMID:
23188382
46.

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.

Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ.

J Immunother. 2012 Nov-Dec;35(9):711-5. doi: 10.1097/CJI.0b013e3182742c27.

PMID:
23090080
47.

From the "greenhouse" to reality: challenges faced by graduates of in-prison batterers intervention program.

Enosh G, Buchbinder E, Smith LN, Shafir O.

J Interpers Violence. 2013 Mar;28(5):910-37. doi: 10.1177/0886260512459382. Epub 2012 Oct 15.

PMID:
23071084
48.

In-home intervention with families in distress: changing places to promote change.

Waisbrod N, Buchbinder E, Possick C.

Soc Work. 2012 Apr;57(2):121-32.

PMID:
23038874
49.

The coping experience of parents of a child with retinoblastoma-malignant eye cancer.

Hamama-Raz Y, Rot I, Buchbinder E.

J Psychosoc Oncol. 2012;30(1):21-40. doi: 10.1080/07347332.2011.633977.

PMID:
22269074
50.

Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.

Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e615-22. doi: 10.1016/j.ijrobp.2011.04.045. Epub 2011 Jun 12.

PMID:
21658854

Supplemental Content

Loading ...
Support Center